Targeting mast cells with imatinib, which inhibits the receptor tyrosine kinase KIT, may decrease airway hyperresponsiveness and improve symptoms in patients with severe, poorly controlled asthma, according to a proof-of-principle clinical trial.
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
While the incidence rate of acute respiratory distress syndrome (ARDS) in Singapore is comparable to the reported values in Europe, the compliance with protective ventilation parameters was inadequate, a new observational study reports.
Strength exercises with both arms raised above the shoulders pose a serious challenge to patients with chronic obstructive pulmonary disease (COPD) compared with other exercise variations, a study has found. Double-arm elevation above shoulder level particularly increases symptoms and cardiovascular demand, as well as delays heart rate (HR) recovery.
The presence of whooping or post-tussive vomiting should rule in a possible diagnosis of pertussis in adult patients, but a diagnosis should be ruled out in the absence of a paroxysmal cough or the presence of fever, according to a meta-analysis. In paediatric patients, on the other hand, post-tussive vomiting is not as useful as a clinical diagnostic test.
The second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) dacomitinib improved progression-free survival (PFS) by an additional 5 months compared with gefitinib in patients with EGFR-positive non-small cell lung cancer (NSCLC), according to results of the open-label, phase III ARCHER 1050* trial.
Larotrectinib delivers durable response across diverse cancer types, including paediatric and adult cancers, according to an interim analysis of three ongoing trials presented at the ASCO 2017 Annual Meeting.
In a Singaporean cohort, greater infant weight gain during the first 15 months of life reduces the risk of sensitization to allergens, a new study shows. However, no effect on combinations of symptoms is observed.
The second-generation ALK inhibitor alectinib significantly improves progression-free survival (PFS) with fewer adverse events (AEs) in Japanese patients with ALK-positive non-small cell lung cancer (NSCLC) compared with the current first-line therapy crizotinib, reveals an interim analysis of the J-ALEX* study. Follow-up of an additional 10 months showed similar results, as presented in the ASCO 2017 Annual Meeting.
Tiotropium Respimat is superior over Handihaler in improving time of sleep spent with sleeping oxygen saturation below 90 (TST90) and sleep parameters in patients with chronic obstructive pulmonary disease (COPD) as performed in a randomised, open-label, parallel group trial.
The BRAF inhibitors vemurafenib and dabrafenib, currently approved for use in advanced melanoma, are also effective in a subset of lung adenocarcinoma patients with BRAF mutations, according to a retrospective European trial presented at the European Lung Cancer Conference (ELCC) held in Geneva, Switzerland.